<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883035</url>
  </required_header>
  <id_info>
    <org_study_id>2019SDU-QILU-02</org_study_id>
    <nct_id>NCT03883035</nct_id>
  </id_info>
  <brief_title>Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary System</brief_title>
  <official_title>Utilization of Real-time Automatic Quality-control System in the Detection of Gastric Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanqing Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study was to develop an automatic quality-control system and assess the
      performance of this system in quality control of esophagogastroduodenoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the researchers firstly developed an automatic quality-control system, name as
      EAS. Next, the researchers applied the system in a endoscopic center and designed a
      prospective randomised controlled trial to investigate the performance of the system in
      quality control of esophagogastroduodenoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>detection rate of gastric neoplasms</measure>
    <time_frame>8 months</time_frame>
    <description>detection rate of gastric neoplasms in different groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean number of gastric neoplasms detected</measure>
    <time_frame>8 months</time_frame>
    <description>mean number of gastric neoplasms detected per procedure in different groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean inspection completeness</measure>
    <time_frame>8 months</time_frame>
    <description>inspection completeness per procedure in different groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean inspection time</measure>
    <time_frame>8 months</time_frame>
    <description>inspection time per procedure in different groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>errors of EAS</measure>
    <time_frame>8 months</time_frame>
    <description>errors of EAS in EAS-aided group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1060</enrollment>
  <condition>Esophagogastroduodenoscopy</condition>
  <arm_group>
    <arm_group_label>EAS-aided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>esophagogastroduodenoscopy examination with the assistance of automatic quality-control system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>automatic quality-control system</intervention_name>
    <description>Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.</description>
    <arm_group_label>EAS-aided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing EGD examination with anaesthesia;

          -  patients able to give informed consent.

        Exclusion Criteria:

          -  patients with the contraindications to EGD examination;

          -  patients with a prior EGD examination within 1 year before the trial;

          -  patients with frankly upper gastrointestinal malignant lesions that were apparent on
             endoscopy;

          -  a history of upper gastrointestinal cancers;

          -  allergic to anaesthetic in previous medical history;

          -  patients refused to participate in the trial;

          -  the EGD procedure cannot be completed due to stenosis, obstruction, solid food, or
             complications of anaesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Esophagogastroduodenoscopy</keyword>
  <keyword>gastric neoplasm</keyword>
  <keyword>artificial intelligence</keyword>
  <keyword>quality control</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

